| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2801960701031 | 196070103 | RETROVIR CAPS 100MG/CAP BTx100 (σε BLISTERS) (σε BLISTERS) | 80.08 | 84.00 | 106.85 |
| 05/2018 | 2801960702014 | 196070201 | RETROVIR CAPS 250MG/CAP BTx40 (σε BLISTER PVC/AL) (σε BLISTER PVC/AL) | 39.25 | 41.17 | 56.73 |
| 05/2018 | 2801960703011 | 196070301 | RETROVIR C/S.SOL.IN 200MG/20ML VIAL BTx5 VIALSx20 ML | 37.51 | 39.35 | 54.23 |
| 05/2018 | 2801960704018 | 196070401 | RETROVIR ORAL.SOL 50MG/5ML FLx200 ML +δοσιμετρική σύριγγα 10 ML +δοσιμετρική σύριγγα 10 ML | 8.70 | 9.12 | 12.57 |
For the treatment of human immunovirus (HIV) infections.
Zidovudine, a structural analog of thymidine, inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA.
Symptoms of overdose include fatigue, headache, nausea, and vomiting. LD<sub>50</sub> is 3084 mg/kg (orally in mice).
Rapid and nearly complete absorption from the gastrointestinal tract following oral administration; however, because of first-pass metabolism, systemic bioavailability of zidovudine capsules and solution is approximately 65% (range, 52 to 75%). Bioavailability in neonates up to 14 days of age is approximately 89%, and it decreases to approximately 61% and 65% in neonates over 14 days of age and children 3 months to 12 years, respectively. Administration with a high-fat meal may decrease the rate and extent of absorption.
0.5-3 hours
As in adult patients, the major route of elimination was by metabolism to GZDV. After intravenous dosing, about 29% of the dose was excreted in the urine unchanged and about 45% of the dose was excreted as GZDV
* 0.65 +/- 0.29 L/hr/kg [HIV-infected, Birth to 14 Days of Age] * 1.14 +/- 0.24 L/hr/kg [HIV-infected, 14 Days to 3 Months of Age] * 1.85 +/- 0.47 L/hr/kg [HIV-infected, 3 Months to 12 Years of Age]